Distinguished in Large-Cell Immunoblastic Lymphoma

Dr. Connie W. Batlevi

Oncology
1275 York Ave, Box 330, 
New York, NY 
Clinical Trials:Currently Recruiting for 2 Trials
Distinguished in Large-Cell Immunoblastic Lymphoma
1275 York Ave, Box 330, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Connie Batlevi is an Oncologist in New York, New York. Dr. Batlevi is rated as a Distinguished provider by MediFind in the treatment of Large-Cell Immunoblastic Lymphoma. Her top areas of expertise are Non-Hodgkin Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Lymphoma, and Bone Marrow Aspiration.

Her clinical research consists of co-authoring 63 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in NY
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
MetroPlus Health
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

1275 York Ave, Box 330, New York, NY 10065

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma
Enrollment Status: Recruiting
Publish Date: October 01, 2025
Intervention Type: Combination product, Drug
Study Drugs: Tazemetostat, Lenalidomide, Rituximab
Study Phase: Phase 3
An Exploratory Study to Correlate the Level of Cell-free DNA With Response to First-line Treatment in Patients With Follicular Lymphoma
An Exploratory Study to Correlate the Level of Cell-free DNA With Response to First-line Treatment in Patients With Follicular Lymphoma
Enrollment Status: Recruiting
Publish Date: August 19, 2025
Intervention Type: Diagnostic test, Other
Study Phase: Phase 1
A Single Arm, Open-label, Multi-centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO3, a CAR T Cell Treatment Targeting CD19 and CD22 With Anti Programmed Cell Death Protein 1 (PD1) Antibody in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
A Single Arm, Open-label, Multi-centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO3, a CAR T Cell Treatment Targeting CD19 and CD22 With Anti Programmed Cell Death Protein 1 (PD1) Antibody in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
Enrollment Status: Terminated
Publish Date: July 14, 2025
Intervention Type: Biological
Study Drugs: AUTO3, cyclophosphamide, fludarabine, pembrolizumab
Study Phase: Phase 1/Phase 2
Phase I Study of N-Acetylcysteine to Optimize Metabolic Tumor Microenvironment in CD19 CAR T-cell Therapy in Lymphoma
Phase I Study of N-Acetylcysteine to Optimize Metabolic Tumor Microenvironment in CD19 CAR T-cell Therapy in Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: May 18, 2025
Intervention Type: Drug
Study Drug: N-Acetylcysteine
Study Phase: Phase 1
Open-label, Single-Arm, Phase 2 Study of Oral HDAC-inhibitor Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma (FORERUNNER)
Open-label, Single-Arm, Phase 2 Study of Oral HDAC-inhibitor Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma (FORERUNNER)
Enrollment Status: Active_not_recruiting
Publish Date: April 10, 2025
Intervention Type: Drug
Study Drug: Abexinostat
Study Phase: Phase 2
Phase I/II Clinical Trial of Copanlisib and Ibrutinib in Mantle Cell Lymphoma
Phase I/II Clinical Trial of Copanlisib and Ibrutinib in Mantle Cell Lymphoma
Enrollment Status: Completed
Publish Date: December 14, 2022
Intervention Type: Drug
Study Drugs: Copanlisib, Ibrutinib
Study Phase: Phase 1/Phase 2
Phase Ib Clinical Trial of Buparlisib and Ibrutinib in Mantle Cell Lymphoma, Follicular Lymphoma and Diffuse Large B Cell Lymphoma
Phase Ib Clinical Trial of Buparlisib and Ibrutinib in Mantle Cell Lymphoma, Follicular Lymphoma and Diffuse Large B Cell Lymphoma
Enrollment Status: Completed
Publish Date: October 10, 2022
Intervention Type: Drug
Study Drugs: Buparlisib, Ibrutinib
Study Phase: Phase 1
View 5 Less Clinical Trials

60 Total Publications

Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated With R-GemOx: A Multicenter Cohort Study.
Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated With R-GemOx: A Multicenter Cohort Study.
Journal: American journal of hematology
Published: October 01, 2024
Similar Doctors
Elite in Large-Cell Immunoblastic Lymphoma
Dr. Tatyana A. Feldman
Oncology | Hematology
Elite in Large-Cell Immunoblastic Lymphoma
Dr. Tatyana A. Feldman
Oncology | Hematology

Regional Cancer Care Associates LLC

92 2nd St, 
Hackensack, NJ 
 (9.8 miles away)
201-996-5900
Languages Spoken:
English, Russian
See accepted insurances
Accepting New Patients
Offers Telehealth

Tatyana Feldman is an Oncologist and a Hematologist in Hackensack, New Jersey. Dr. Feldman is rated as an Elite provider by MediFind in the treatment of Large-Cell Immunoblastic Lymphoma. Her top areas of expertise are Classical Hodgkin Lymphoma, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Feldman is currently accepting new patients.

Distinguished in Large-Cell Immunoblastic Lymphoma
Dr. Andrew D. Zelenetz
Oncology
Distinguished in Large-Cell Immunoblastic Lymphoma
Dr. Andrew D. Zelenetz
Oncology

Memorial Hematology Lymphoma Group

530 E 74th St, 
New York, NY 
 (0.3 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Andrew Zelenetz is an Oncologist in New York, New York. Dr. Zelenetz is rated as an Elite provider by MediFind in the treatment of Large-Cell Immunoblastic Lymphoma. His top areas of expertise are Non-Hodgkin Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma (MCL), and Diffuse Large B-Cell Lymphoma (DLBCL).

Distinguished in Large-Cell Immunoblastic Lymphoma
Dr. Lori A. Leslie
Oncology | Hematology
Distinguished in Large-Cell Immunoblastic Lymphoma
Dr. Lori A. Leslie
Oncology | Hematology

Regional Cancer Care Associates LLC

30 Prospect Ave, 
Hackensack, NJ 
 (9.8 miles away)
201-996-2210
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Lori Leslie is an Oncologist and a Hematologist in Hackensack, New Jersey. Dr. Leslie is rated as an Elite provider by MediFind in the treatment of Large-Cell Immunoblastic Lymphoma. Her top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Chronic Lymphocytic Leukemia (CLL), Bone Marrow Aspiration, and Lymphadenectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Batlevi's expertise for a condition
ConditionClose
View All 10 Advanced Conditions
View All 13 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile